BioCentury
ARTICLE | Product R&D

Expanding small molecule horizons

How 5AM newco Expansion Therapeutics is hitting RNA targets with small molecules

January 3, 2018 9:40 PM UTC

With a platform boasting more than a decade of preclinical rigor and $55.3 million in series A funding, Expansion Therapeutics Inc. is the latest company to step into the RNA-binding small molecule arena. The newco is setting its sights first on pathogenic RNA repeat expansions responsible for a range of rare genetic disorders.

As the most recent graduate of 5AM Ventures’ 4:59 Initiative incubator, Expansion emerged from stealth mode yesterday, after twelve months’ work with scientific founder Matthew Disney, a pioneer in the field who is professor of chemistry at The Scripps Research Institute...